This recombinant monoclonal antibody is designed as a research-grade biosimilar to Vopratelimab, targeting the Inducible T-cell CO-Stimulator (ICOS, CD278). ICOS is a critical co-stimulatory molecule expressed on activated T cells that plays a pivotal role in T-cell activation, differentiation, and effector function. Upon binding to its ligand ICOSL, ICOS enhances T-cell responses and promotes the development and function of follicular helper T cells and regulatory T cells. Dysregulation of ICOS signaling has been implicated in various immune-mediated conditions and represents an important checkpoint in cancer immunology, where ICOS-expressing tumor-infiltrating lymphocytes contribute to anti-tumor immunity.
Vopratelimab is an investigational agonistic antibody that stimulates ICOS signaling to enhance anti-tumor immune responses, currently under clinical evaluation for various solid tumors. This biosimilar antibody provides researchers with a valuable tool for investigating ICOS-mediated immune mechanisms, studying T-cell co-stimulation pathways, and exploring novel immunotherapeutic strategies in oncology and autoimmune disease models. It enables detailed characterization of ICOS function in immune regulation and tumor microenvironment dynamics.
Email: support@cusabio.com
Distributors Worldwide